-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hebei Ren Heyikang Pharmaceuticals to copy the 4 categories of submitted benzoic acid left ammonia chloride flat tablets listed applications into the administrative approval stage.
meters intranet data show that in 2019, China's public medical institutions and urban retail pharmacy terminal sales of more than 5 billion yuan, an increase of 8.02 percent year-on-year, there is no enterprise product evaluation.
Source: The official website of the State Drug Administration benzoic acid L-Achloride is a calcium ion antagonist (CCB)-type anti-hypertensive drug, for benzodiacyte chlorine-leveling zodiasphere, retaining the role of anti-hypertension at the same time can reduce edema and other side effects.
There are currently 11 domestic enterprises with benzoic acid L-Achloride tablet production approval, Minanet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) and China's urban retail pharmacy terminal total sales of more than 5 billion yuan, up 8.02% YoY, Shi Huida market share of more than 60%.
Pharmaceutical Network September 30, 2019 in China's public medical institutions terminal cardiovascular system drug competition pattern, benzoic acid L-Achloride tablets with 2.98 percent of the market share ranked sixth;
Table: Declaration of consistent evaluation of benzoic acid L-Chloride tablets (including new classification) Source: MED2.0 China Drug Review Database Mi-Net data show that four enterprises have submitted benzoic acid L-Chloride Flat tablet consistent evaluation of supplementary applications, are currently in the "in the review and approval (in the drug review center)" state, 3 enterprises to copy 4 categories to submit the product listing application, of which Hebei Ren Heyikang Pharmaceutical products have entered the administrative approval stage, is expected to be the first evaluation.
.
